Bendamsutine in Mantle cell Lymphoma - Experience from Cancer Institute
Abstract
Introduction : Mantle cell lymphoma is an aggressive subbytpe of NHL with dismal prognosis. Bendamustine and Riutximab based regimens are considered as one of the preferred options.Here we report our experience with Bendamustine based regimens in Mantle cell lymphoma
Methods: We conducted a retrospective analysis of patients with Mantle cell lymphoma treated with Bendamustine based regimens from 2010-2015. We analysed the baseline characteristics, treatment details,toxicity and outcome. Survival was estimated using Kaplan Meier method.
Results: Twenty patients were included in the analysis. Median age was 59 years and 74% were males. All patients presented in Stage III/IV and 74% (n=14) had bone marrow involvement. Five patients (26%) had leukemic presentation. Twelve patients (65%) received treatment on first line setting and rest in relapsed setting. Commonest regime used was BR (n=9,47%) followed by Single Agent Bendamustine (n=7,37%) and combination of Bendamustine, Vincristine and Prednisolone (n=3,17%). Median number of cycles were 6 (range 1-8). Overall response rate (ORR) 73% with 47 % CR and 26% PR. ORR was 75% in first line and 71% in the second line setting. At the end of 25 months of follow up 1 year PFS was 73 % and 2 year PFS was 47%. Median OS was not reached and 2 year OS was 68%. Commonest toxicity observed was skin rash (n=8,42%) followed by leukopenia (n=3, 16%) and thrombocytopenia (n=2,10%).
Conclusions: Though a retrospective study with small numbers this shows that bendamsutine based regimens show good efficacy with favourable toxicity profile in Indian patients with Mantle cell lymphoma.
Full Text:
PDFReferences
Gujral S, Agarwal A, Gota V, Nair R, Gupta S, Pai S K, Sanger M,
Shet T, Subramanian P G, Muckaden M, Laskar S. A
clinicopathologic study of mantle cell lymphoma in a single center study
in India. Indian J Pathol Microbiol 200851315-22.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R,
et al. The 2016 revision of the World Health Organization classification
of lymphoid neoplasms. Blood. 2016 May 19;127(20):2375.
Becker M, Tschechne B, Reeb M, Schwinger U, Bruch H-R, Frank M,
et al. Bendamustine as first-line treatment in patients with advanced
indolent non-Hodgkin lymphoma and mantle cell lymphoma in German
routine clinical practice. Ann Hematol. 2015;94(9):1553–8.
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus
CHOP plus rituximab as first-line treatment for patients with
indolent and mantle-cell lymphomas: an open - label, multicentre,
randomised, phase 3 non-inferiority trial. The Lancet.
(9873):1203–10.
Chandan Krushna Das; Ajay Gogia ; Lalit Kumar; Atul Sharma;
Mehar Chand Sharma; Saumya Ranjan Mallick. Mantle Cell
Lymphoma: A North Indian Tertiary Care Centre Experience. Asian
Pac J Cancer Prev 2016 Oct 117104583-4586.
Distribution of various subtypes of non-Hodgkin’s lymphoma in India: a
study of 2773 lymphomas using R.E.A.L. and WHO Classifications.
Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood.
Aug 20;114(8):1469.
Herold M, Schulze A, Niederwieser D, Franke A, Fricke H J, Richter
P, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced
indolent non-Hodgkin’s lymphoma and mantle cell lymphoma:
results of a randomised phase III trial (OSHO# 19). J Cancer
Res Clin Oncol. 2006;132(2):105–12.
Osmani AH, Masood N. Single centre study of using bendamustine in the treatment of B-cell malignancies. J Pak
Med Assoc 2013 Jun636702-6.
Malipatil B, Ganesan P, Sundersingh S, Sagar TG. Preliminary experience with the use of bendamustine: a
peculiar skin rash as the commonest side effect. Hematol Oncol
Stem Cell Ther. 2011 Oct 1;4(4):157–60.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An initiative of The Tamil Nadu Dr M.G.R. Medical University